Navigation Links
Unlocking the genetic and molecular mystery of soft-tissue sarcoma

BostonNOVEMBER 30, 2011Scientists at Joslin Diabetes Center in Boston have uncovered important molecular and genetic keys to the development of soft-tissue sarcomas in skeletal muscle, giving researchers and clinicians additional targets to stop the growth of these often deadly tumors.

Published in the Proceedings of the National Academy of Sciences, the study identified two major molecular signaling pathways (the Ras and mTOR pathways) that are common in tumor growth and development. These molecular pathways regulate cell growth and division, two cellular properties whose over-activation are hallmarks of cancer biology.

"In humans, some sarcomas respond to chemotherapy," says lead author Amy J. Wagers, PhD, an associate professor of stem cell and regenerative biology at Harvard Medical School and Joslin Diabetes Center, "but many don't. With these findings, we have vetted a list of new candidate targets whose inhibition may lead to regression of these tumors. "

Many soft-tissue sarcomas, which develop in certain tissues such as bone and muscle, carry specific genetic mutations or unique gene signatures, which can allow scientists to develop more precise, targeted therapies. Wagers and her colleagues engineered a tumor system in mice by introducing into mouse skeletal muscle a cancer-carrying gene, or oncogene, known to cause tumors in humans. They used this engineered system to identify a small set of genes that are active in sarcoma tumors.

There are many different types of soft-tissue sarcomas, which develop in tissues that connect, support or surround other structures and organs, including muscle, tendons, nerves, fat and blood vessels. If diagnosed early, treatment, primarily through surgical removal of the tumor, radiation therapy or chemotherapy, can be effective. If the tumor has spread, however, the tumor can be controlled only for a period of time, but treatment does not often cure the disease.

By inducing these tumors in mice, Wagers says the scientists knew when the tumors would form in the mice and where in the body they would develop, which helped them better understand the molecular and genetic pathways underlying the disease. With this knowledge, researchers may be able to develop new intervention strategies that interfere with these genetic activities and stop the growth of this type of tumor.

"With the engineered system we developed, we can find new fragile points in the tumor to target," says first author Simone Hettmer, MD, a pediatric oncologist at the Dana-Farber/Children's Hospital Cancer Center, who treats children with these tumors. In addition, she adds, the system allows scientists to look at the genetic changes in sarcomas and how they interact with the development of tumors and can be applied to sarcomas in tissues other than skeletal muscle.

Surprisingly, says Wagers, the researchers found they could induce tumors using several different "beginning" cells. The scientists generated tumor cells using stem cell-like cells that go on to make either muscle or other connective tissues. Tumors that develop from muscle cells were rhabdomyosarcomas, the most common form of soft-tissue sarcoma seen in children, while tumors that developed from non-muscle cells represented other types of sarcoma.

Wagers and her colleagues are now working on establishing a similar engineered model using human cells to test the effectiveness of anti-sarcoma medications. These preclinical experiments are designed to identify the most promising candidates for the treatment of soft-tissue sarcoma that ultimately will be pursued in human clinical trials. Early studies have identified several chemical compounds that, in cell cultures at least, appear to slow the growth of sarcoma cells.


Contact: Jeffrey Bright
Joslin Diabetes Center

Related medicine news :

1. Unlocking jams in fluid materials
2. UNC researchers inch closer to unlocking potential of synthetic blood
3. Unlocking the secret of beauty: Scientists discover the complexities of attractive female bodies
4. Unlocking the Immune System's Response to Infection and Injury
5. CU-Boulder led study of smoking twins points to growing influence of genetic factors
6. Increasing dosage of clopidogrel for patients with genetic variation improves response to medication
7. Combination epigenetic therapy clinical trial results
8. Epigenetic therapy shows promise in hard-to-treat lung cancer
9. Breakthrough in understanding the genetics of high blood pressure
10. Possible Genetic Link to Autism Identified
11. Ohio State researchers design a viral vector to treat a genetic form of blindness
Post Your Comments:
Related Image:
Unlocking the genetic and molecular mystery of soft-tissue sarcoma
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing ... this disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition ...
(Date:11/25/2015)... ... November 25, 2015 , ... An unlikely ... resulting in a way for homeless people to have a more dignified and ... new initiative whereby they are repurposing plastic bags into sleeping mats for the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since ... providing comprehensive solutions involving adult stem cell therapies to patients with chronic degenerative ... “Regenestem” name as a Registered Trademark (RTM). , Organizations are required to hold ...
(Date:11/24/2015)... (PRWEB) , ... November 25, 2015 , ... ... and monitoring. Their Care Plan software creates an agreement between the practice ... care plan, including financial, scheduling, monitoring, notification, and projections. Click here ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... and BERN, Switzerland , November ... ARTORG Center for Biomedical Engineering Research of the University ... Division of Endocrinology, Diabetes and Clinical Nutrition of the ... start of an exclusive collaboration to develop a novel ... for the personalised delivery of insulin for diabetic patients ...
(Date:11/24/2015)... FLINT, Mich. , Nov. 24, 2015 Diplomat ... , Senior Vice President of Clinical Services, Education and Human ... (AIS) online webinar, "Oral Oncology Drugs: Health Plan Strategies for ... co-presenting with Beckie Fenrick , a consultant with the ... The webinar will ...
(Date:11/24/2015)... 24, 2015 iRhythm Technologies, Inc. , a leading ... announced that it will participate in the 27th Annual Piper Jaffray ... New York, NY . Kevin King , Chief ... 1, 2015 at 8:50am ET. --> ... . --> . --> iRhythm is ...
Breaking Medicine Technology: